linjc16/ctgov huggingface dataset:
Ease-it Spray for the Treatment of Fire Ant Stings

Study Overview
=================
Brief Summary
-----------------
The application of Ease-it Spray will alleviate pain secondary to fire ant stings more quickly than placebo.

Conditions
-----------------
Insect Bites and Stings

Intervention / Treatment
-----------------
* Procedure: Ease-It Spray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AD soldier in US Army Ages 18-60 Volunteer Absence of serious medical condition Past allergic reactions Asthma History of (h/o) IFA sting Exclusion Criteria: Inability to provide informed consent Known h/o hymenoptera allergic reaction Allergy to any component of the treatments Inability to follow-up Active medical condition Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Ease-It Spray|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Adiponectin and Insulin Resistance in Diabetic Nephropathy

Study Overview
=================
Brief Summary
-----------------
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Official Title
-----------------
Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Conditions
-----------------
Diabetic Nephropathy

Intervention / Treatment
-----------------
* Drug: Losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetic nephropathy CKD at stage 1 4 Exclusion Criteria: Type 1 diabetes or nondiabetic renal disease An elevated plasma K level.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Losartan|Angiotensin II Type 1 Receptor Blockers|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GFR, HbA1c and the adiponectin concentration |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers
Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery

Study Overview
=================
Brief Summary
-----------------
It is a trial aimed to evaluate the ejection fraction in the preoperative phase and during follow-up in two groups of subjects undergoing major orthopedic surgery: the first consisting of subjects without history of cardiac disease, and the second from subjects with a history of cardiopulmonary disease

Official Title
-----------------
Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery

Conditions
-----------------
Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: < or equal 18 and > or equal 85 years major orthopedic surgery rehabilitation at our site a positive history for the cardiopathic group Exclusion Criteria: Age: > 85 and < 18 impossibility to participate to the rehabilitative protocol or come to the follow up visit lack of consensus previous acute cerebrovascular and / or cardiological events within 6 months prior to enrollment previous myocardial (percutaneous and / or surgical) revascularization interventions within the 6 months prior to enrollment previous (even in pediatric age) interventions of surgical correction of congenital heart disease severe heart failure reimplantation of prosthesis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| subjects without a history of cardiac disease<br> | |
| subjects with a history of cardiac disease<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of rehabilitation on the ejection fraction (FE) in cardiopathic and non-cardiac patients undergoing major orthopedic surgery | Left ventricular evaluation of ejection fraction (FE) at 6 months in cardiopathic patients with vitamin D deficiency subjected to supplementation with calcifediol | 6 months |
Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections

Study Overview
=================
Brief Summary
-----------------
The research question to be addressed is whether indirect phototherapy based activation of the body's alternative cellular energy (ACE) pathway will lead to expedited healing of active herpes simplex virus (HSV) and herpes zoster virus (HZV)skin lesions, and also possibly inhibit both latent HSV infections and residual HZV infections.

Official Title
-----------------
A Research Study Examining the Effectiveness of Distant Activation of ACE Pigments Associated With Recurrent Human Herpes Simplex Virus-Induced Skin Lesions.

Conditions
-----------------
Herpes Simplex, Herpes Zoster

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of active, latent or residual HSV or HZV infection Exclusion Criteria: Unwilling or unable to provide Informed Consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with active oral or genital HSV skin lesions | |
| 2<br>Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment | |
| 3<br>Patients with active shingles/zoster | |
| 4<br>Patients with post herpetic neuralgia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expedited healing of active lesions |  | Within 1 day following therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of lesions and/or symptoms |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
herpes, HSV, zoster, HZV, shingles
Ultrasound Guided Intra-uterine Device Insertion

Study Overview
=================
Brief Summary
-----------------
Different studies have been made in an attempt to reduce the pain and the duration of the process of outpatient insertion of the intrauterine device. in this trial, the investigators aim to insert the IUD under ultrasonographic guidance, which can help to reduce the pain, decrease the process of insertion, in addition, it reduces the incidence of malposition of IUD as well as the risk of complications.

Official Title
-----------------
A Further Step Towards Painless Intrauterine Device Insertion, a Randomized Control Trial

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Device: intrauterine device TCu 380A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females desiring contraception with the use of IUD Exclusion Criteria: Are pregnant or think they may be pregnant Septic pregnancy or abortion Have unexplained abnormal vaginal bleeding Have untreated cervical cancer Have malignant gestational trophoblastic disease Have uterine cancer Have uterine abnormalities Have or may have had a pelvic infection within the past three months Have or may have any sexually transmitted disease Have pelvic tuberculosis Are postpartum between 48 hours and 4 weeks Have benign gestational trophoblastic disease Have ovarian cancer Have AIDS (unless clinically well on anti-retroviral therapy)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound guided group<br>the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released. | Device: intrauterine device TCu 380A<br> <br> * Other names: TCu 380A;|
| Experimental: Non ultrasound guided group<br>the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. | Device: intrauterine device TCu 380A<br> <br> * Other names: TCu 380A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of degree of pain during IUD insertion | Pain will be assessed by the use of visual analog scale, Pain rating scale | 6 months |
Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank

Study Overview
=================
Brief Summary
-----------------
The constitution of a biological samples bank, attached to epidemiological studies Cohort F-CCSS on iatrogenic effects of treatment of childhood cancer, will identify genetic variants that can modulate the iatrogenic risks of these treatments. The main objective is to provide a biological samples bank to consider, besides the carcinogenic risks, the risk of other iatrogenic diseases in these children, in particular cardiac, cerebrovascular, lung, bone and kidney. These conditions can be very incapacitating and in some cases, fatal. Their impact, however, is poorly estimated as occurring in adulthood, they are rarely made in relation to the treatment received in childhood. The overall project is expected to eventually better define the iatrogenic effects prevention strategies for cancer treatment.

Official Title
-----------------
Study of Iatrogenic Effects of Treatment for Childhood Cancer - Constitution of a Biological Samples Bank as Part of a Cohort of Patients (Cohort FCCSS)

Conditions
-----------------
Paediatric Malignancies

Intervention / Treatment
-----------------
* Procedure: saliva samples
* Procedure: blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated for a first cancer in childhood Adult patients Signed informed consent Patient insured or enjoying a social security scheme Exclusion Criteria: Minor patients Under legal protection measure patients Refusal of consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated for cancer in childhood<br> | Procedure: saliva samples<br> <br> Procedure: blood samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of genetic factors who might lead to secondary iatrogenic pathology due to treatment of a childhood cancer |  | seven years |
RAPP-children, Rhinitis & Asthma in Patient Perspective: Development and Validation of a Questionnaire for Quality of Life Evaluation in Children With Asthma and Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
This observational study aims at developing and validating a simple questionnaire to be routinely applied in the clinical practice, for the evaluation of the quality of life in children with concomitant asthma and allergic rhinitis. The study consists of two phases: Phase 1: Development of the RAPP-children questionnaire starting from the validated RHINASTHMA-children questionnaire. Phase 2: Administration and validation of the RAPP-children questionnaire. 150 children with concomitant asthma and allergic rhinitis will be followed-up for one month. Both at baseline and after one month, the RAPP children and several other standardized questionnaires will be administered.

Official Title
-----------------
RAPP-children, Rhinitis & Asthma in Patient Perspective: Development and Validation of a Questionnaire for Quality of Life Evaluation in Children With Asthma and Allergic Rhinitis

Conditions
-----------------
Asthma, Allergic Rhinitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 6 and 11 years Concomitant asthma and allergic rhinitis Males and Females Exclusion Criteria: Immunological and metabolic systemic disease Major malformations of the upper airways Active smoker

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 150 children with concomitant asthma and rhinitis<br>Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RAPP-children response patterns | Multivariate analyses of the responses to the RAPP-children questions | 1 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RHINASTHMA-children response patterns | Frequency distributions of the responses to the RHINASTHMA-children | 1 months | 
| C-ACT response patterns | Frequency distributions of the responses to the C-ACT (Childhood Asthma Control Test) | 1 months | 
| VAS response pattern | Frequency distribution of the response to the VAS (Visual Analog Scale) | 1 months | 
| Kiddy-KINDL response patterns | Frequency distributions of the response to the Kiddy-KINDL | 1 months | 
| Pulmonary function: FEV1 | Forced expiratory volume in the first second | 1 months | 
| Pulmonary function: FVC | Forced vital capacity | 1 months | 
| Pulmonary function: FEF25-75 | Forced expiratory flow at 25-75% | 1 months |
Multicenter Trial of Prednisone in Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.

Official Title
-----------------
Multicenter Trial of Prednisone in Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Drug: Prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Alzheimer's disease who are in stable medical condition Exclusion Criteria: Patients with diabetes or severe osteoporosis

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Prednisone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prednisone, Alzheimer's disease, Anti-inflammatory agents
Survey on Supplement Use in Mitochondrial Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn about the use of nutritional supplements in patients with mitochondrial disease.

Detailed Description
-----------------
Our goal is to better assess which nutritional supplements are prescribed to patients with mitochondrial disorders, the monitoring obtained and whether any subjective improvements are noted by the patients or their caregivers.

Official Title
-----------------
Survey on Supplement Use in Mitochondrial Disease

Conditions
-----------------
Mitochondrial Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: NAMDC Clinical Registry or RDCRN Contact Registry participant Diagnosis of a mitochondrial disease confirmed by either electron transport chain abnormalities or molecular testing. Exclusion Criteria: Lack of participation in NAMDC or RDCRN registries Diagnosis of mitochondrial disorder not confirmed by ETC studies or molecular diagnosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of nutritional supplement use in patients with mitochondrial disease. | This cross-sectional survey will assess nutritional supplements used by patients with mitochondrial disease. | Up to one year after study activation. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the attitudes of patients and parents towards use of nutritional supplements in patients with mitochondrial disease | This cross-sectional survey will assess patients' and parents' attitudes (comfort level and perceptions of efficacy) of use of nutritional supplements in patients with mitochondrial disease. | Upt to one year after study activation. |
The Swiss Venous Thromboembolism Cohort 65+

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective multicenter cohort study is to examine long-term medical outcomes, quality of life, and medical resource utilization in elderly patients (>= 65 years) with acute venous thromboembolism (i.e., acute pulmonary embolism and/or deep vein thrombosis)

Official Title
-----------------
Swiss Venous Thromboembolism Cohort Study of Elderly Patients With Acute Venous Thromboembolism

Conditions
-----------------
Venous Thromboembolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Objectively confirmed acute pulmonary embolism and/or deep vein thrombosis Age >=65 years Exclusion Criteria: Thrombosis at a different site than lower limb Catheter-related thrombosis Insufficient spoken language ability in German or French Follow-up not possible (e.g., terminally ill patients) Informed consent not possible (e.g., severe dementia) Prior enrolment in the study

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Venous thromboembolism recurrence |  | 3-48 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall mortality |  | 3-48 months | 
| Major bleeding |  | 3-48 months | 
| Post-thrombotic syndrome |  | 3-48 months | 
| Generic and disease-specific health-related quality of life |  | 3-48 months | 
| Medical resource utilization |  | 3-48 months |